Editorial
doi: 10.1056/NEJMe0901737.
Androgen deprivation in prostate cancer--step by step
Affiliations
- PMID: 19516038
- DOI: 10.1056/NEJMe0901737
Item in Clipboard
Editorial
Androgen deprivation in prostate cancer--step by step
N Engl J Med.
.
Erratum in
- N Engl J Med. 2009 Jul 9;361(2):217
No abstract available
Comment on
-
Duration of androgen suppression in the treatment of prostate cancer.N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095. N Engl J Med. 2009. PMID: 19516032 Clinical Trial.
Similar articles
-
Duration of androgen suppression in the treatment of prostate cancer.N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095. N Engl J Med. 2009. PMID: 19516032 Clinical Trial.
-
Endocrine treatment of prostate cancer.J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review.
-
Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.Hinyokika Kiyo. 2006 Apr;52(4):259-64. Hinyokika Kiyo. 2006. PMID: 16686352
-
[Prostate cancer].Gan To Kagaku Ryoho. 1997 Nov;24(14):2092-7. Gan To Kagaku Ryoho. 1997. PMID: 9388518 Review. Japanese.
-
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21. Eur Urol. 2009. PMID: 19249153 Clinical Trial.
Cited by
-
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.Cell Rep Med. 2024 Oct 15;5(10):101752. doi: 10.1016/j.xcrm.2024.101752. Epub 2024 Sep 30. Cell Rep Med. 2024. PMID: 39353441 Free PMC article.
-
A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy.Transl Androl Urol. 2023 Aug 31;12(8):1336-1350. doi: 10.21037/tau-23-272. Epub 2023 Aug 4. Transl Androl Urol. 2023. PMID: 37680229 Free PMC article. Review.
-
Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway.Int J Nanomedicine. 2017 Mar 31;12:2569-2579. doi: 10.2147/IJN.S130537. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28408824 Free PMC article.
-
Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.Oncotarget. 2013 Mar;4(3):422-32. doi: 10.18632/oncotarget.917. Oncotarget. 2013. PMID: 23518876 Free PMC article.
-
A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.Acta Pharmacol Sin. 2011 Apr;32(4):537-42. doi: 10.1038/aps.2010.236. Epub 2011 Mar 14. Acta Pharmacol Sin. 2011. PMID: 21399652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
